Eli Lilly (LLY) Revenue (2009 - 2025)

Eli Lilly has reported Revenue for 17 years, with the latest figure at $65.2 billion in FY2025.

• For the quarter ending Q1 2026, Revenue rose 55.54% year-over-year to $19.8 billion; the trailing twelve-month figure through Mar 2026 stood at $72.2 billion (up 47.44% YoY), and the FY2025 full-year result was $65.2 billion, up 44.7% from the prior year.
• Revenue for FY2025 stood at $65.2 billion, up from $45.0 billion in the prior year.
• The five-year high for Revenue was $65.2 billion in FY2025, with the low at $28.3 billion in FY2021.
• Historically, Revenue has averaged $40.2 billion across 5 years, with a median of $34.1 billion in 2023.
• Annual changes were most pronounced in 2022 — Revenue increased 0.79% — and 2025, when it surged 44.7%.
• Eli Lilly's Revenue stood at $28.3 billion in 2021, then increased by 0.79% to $28.5 billion in 2022, then increased by 19.56% to $34.1 billion in 2023, then surged by 32.0% to $45.0 billion in 2024, then jumped by 44.7% to $65.2 billion in 2025.
• The last three Revenue figures came in at $65.2 billion (FY2025), $45.0 billion (FY2024), and $34.1 billion (FY2023), per Business Quant data.